基于药性组合的活血化瘀中药的辛苦味性效关系研究
|
摘要
活血化瘀药是临床中最常用的一类药,多为辛、苦味,为了探讨活血化瘀药的药性与功效的内在联系,该研究利用TCMSP平台及Cytoscape 3. 5. 1平台构建温辛肝、温苦肝药性组合交补集蛋白互作网络及靶点疾病网络,并对其进行网络模块分析。结果表明,温肝网络与癌症、高血压、抑郁症等疾病有关,体现出温肝之温阳化气、行气活血、化瘀散结的功效。苦味网络与心肌梗死、癌症、炎症等疾病有关,体现出"苦"可宣泄宣通、泄通则瘀散的功效。辛味网络与癌症、心血管疾病、骨质疏松症等疾病有关,体现出辛味之活血、消散的功效。研究表明,温辛肝、温苦肝药性组合通过调节不同靶点参与不同疾病过程,从而达到活血化瘀的功效。
The herbs for promoting blood circulation and removing blood stasis were used commonly in clinical,and most of them are pungent and bitter. In order to study the nature-effect interrelationship of the herbs for promoting blood circulation and removing blood stasis,the TCMSP platform and Cytoscape 3. 5. 1 platform were used to construct warm-pungent-liver and warm-bitter-liver of the complement and intersection protein interaction network and the target-disease network and the network module was analyzed. As a result,warm-liver target-disease network is associated with diseases such as cancer,hypertension,and depression,which exerts the efficacy of warming Yang and transforming Qi,promoting Qi and activating blood,removing blood stasis and dispersing phlegm. The bitter taste target-disease network is associated with diseases such as myocardial infarction,cancer,inflammation and other diseases,which exerts the efficacy of dissipating the stasis. The pungent taste target-disease network is associated with diseases such as cancer,cardiovascular disease,osteoporosis and other diseases,which exerts the efficacy of invigorating the circulation of blood and eliminating stagnation. The research shows that the medicinal combination of warm-pungent-liver and warm-bitter-liver has the efficacy of promoting blood circulation and removing blood stasis by regulating different targets in different disease processes.
The herbs for promoting blood circulation and removing blood stasis were used commonly in clinical,and most of them are pungent and bitter. In order to study the nature-effect interrelationship of the herbs for promoting blood circulation and removing blood stasis,the TCMSP platform and Cytoscape 3. 5. 1 platform were used to construct warm-pungent-liver and warm-bitter-liver of the complement and intersection protein interaction network and the target-disease network and the network module was analyzed. As a result,warm-liver target-disease network is associated with diseases such as cancer,hypertension,and depression,which exerts the efficacy of warming Yang and transforming Qi,promoting Qi and activating blood,removing blood stasis and dispersing phlegm. The bitter taste target-disease network is associated with diseases such as myocardial infarction,cancer,inflammation and other diseases,which exerts the efficacy of dissipating the stasis. The pungent taste target-disease network is associated with diseases such as cancer,cardiovascular disease,osteoporosis and other diseases,which exerts the efficacy of invigorating the circulation of blood and eliminating stagnation. The research shows that the medicinal combination of warm-pungent-liver and warm-bitter-liver has the efficacy of promoting blood circulation and removing blood stasis by regulating different targets in different disease processes.
引文
[1]黄帝内经·素问[M].田代华整理.北京:人民卫生出版社,2005.
[2]钟赣生.中药学[M].北京:中国中医药出版社,2016:21.
[3]吕春艳,吕邵娃,李国玉,等.中药性味拆分与组合药理效应的研究进展[J].中国中药杂志,2018,43(14):2892.
[4]张建永.丹参山楂组分配伍抗动脉粥样硬化及作用机制研究[D].北京:中国中医科学院,2013.
[5] Vistoli G,Pedretti A,Testa B. Assessing drug-likeness——what are we missing[J]. Drug Discov Today,2008,13(7/8):285.
[6] Ru J,Li P,Wang J,et al. TCMSP:a database of systems pharmacology for drug discovery from herbal medicines[J]. J Cheminform,2014,6(1):13.
[7]魏志成,童东,杨娟,等.基于网络药理学的沙棘总黄酮治疗心肌缺血的作用机制研究[J].中国中药杂志,2017,42(7):1238.
[8] Gaulton A,Bellis L J,Bento A P,et al. ChEMBL:a large-scale bioactivity database for drug discovery[J]. Nucleic Acids Res,2012,40:1100.
[9] Li M,Chen J E,Wang J X,et al. Modifying the DPClus algorithm for identifying protein complexes based on new topological structures[J]. BMC Bioinformatics,2008,9(1):1.
[10] Chin C H,Chen S H,Wu H H,et al. cyto Hubba:identifying hub objects and sub-networks from complex interactome[J].BMC Syst Biol,2014,8(S4):S11.
[11] Tsai C J,Ma B,Nussinov R. Protein-protein interaction networks:how can a hub protein bind so many different partners[J]. Trends Biochem Sci,2009,34(12):594.
[12]陈晨,刘倩,高华.活血化瘀药药理作用研究进展[J].中国药事,2011,25(6):603.
[13]闫风.“五味学说”理论探讨[D].沈阳:辽宁中医药大学,2008.
[14]徐慧,董昌武.雌激素受体基因与心血管系统疾病相关性研究进展[J].医学综述,2013,19(9):1540.
[15] Hebertchatelain E. Src kinases are important regulators of mitochondrial functions[J]. Int J Biochem Cell B,2013,45(1):90.
[16] Dieliconwright C M,Spektor T M,Rice J C,et al. Oestradiol and SERM treatments influence oestrogen receptor coregulator gene expression in human skeletal muscle cells[J]. Acta Physiol,2010,197(3):187.
[17]傅文垚.三种神经退行性疾病相关基因互作网络和药物靶点的比较分析[D].合肥:合肥工业大学,2017.
[18]刘晓霞,翟曜耀,赵越.雌激素受体ERα的功能调控及相关疾病的研究进展[J].中国细胞生物学学报,2011,33(1):65.
[19]赵谊宁,陶陶,张力杰,等.雌激素受体ERα及ERβ与肿瘤关系的研究进展[J].东南大学学报:医学版,2016,35(3):418.
[20]王春战,景华.姜黄素抗炎抗氧化作用的研究进展[J].医学研究生学报,2012,25(6):658.
[21] Bagarolli R A,Saad M J A,Saad S T O. Toll-like receptor 4 and inducible nitric oxide synthase gene polymorphisms are associated with type 2 diabetes[J]. J Diabetes Complicat,2010,24(3):192.
[22]丰瑞兵,陈利锋,王华松,等.益气活血方对佐剂型关节炎大鼠滑膜组织TLR2、TLR9的影响[J].中医药导报,2017,23(17):25.
[23]吕春艳,吕邵娃,李国玉,等.中药复方性味与组分配伍药理效应的研究进展[J].中国中药杂志,2018,43(6):1099.
[24]庄晓峰.卡维地洛对大鼠急性心肌梗死后非梗死区胶原重塑及MMP-13/TIMP-2表达的影响[D].福州:福建医科大学,2006.
[25]肖斌,王耘,郭维嘉,等.中药药性组合及其与功效的关系研究[J].世界科学技术——中医药现代化,2010,12(6):902.
[26]李瑜.不同肾素型高血压患者的靶器官损害及其与ADRBK1基因变异的关联研究[D].乌鲁木齐:新疆医科大学,2015.
[27]姜萍,李晓,李寿松.从中药四气五味归经功效分析丁书文教授治疗高血压病用药特色[J].中华中医药杂志,2013,28(7):1951.
[28]刘晓妍,程宇琪,沈宗霖,等.抑郁症影像遗传学研究进展[J].国际精神病学杂志,2016,43(2):209.
[29]李卫国,付星,杜渐.针灸治疗抑郁症的理论探讨[J].中国中医基础医学杂志,2017,23(11):1596.
[30]陈万青,郑荣寿,张思维,等.2003~2007年中国癌症发病分析[J].中国肿瘤,2012,21(3):161.
[31]邓凯文.活血化瘀法在恶性肿瘤治疗中的应用研究[D].南京:南京中医药大学,2009.
[32]丁琦.当代活血化瘀法治疗肿瘤理论的演变与评价[D].济南:山东中医药大学,2017.
[33]马晓娟,殷惠军,陈可冀.血瘀证与炎症相关性的研究进展[J].中国中西医结合杂志,2007,27(7):669.
[34]马民.血瘀证形成的微观机制研究[D].济南:山东中医药大学,2003.
[2]钟赣生.中药学[M].北京:中国中医药出版社,2016:21.
[3]吕春艳,吕邵娃,李国玉,等.中药性味拆分与组合药理效应的研究进展[J].中国中药杂志,2018,43(14):2892.
[4]张建永.丹参山楂组分配伍抗动脉粥样硬化及作用机制研究[D].北京:中国中医科学院,2013.
[5] Vistoli G,Pedretti A,Testa B. Assessing drug-likeness——what are we missing[J]. Drug Discov Today,2008,13(7/8):285.
[6] Ru J,Li P,Wang J,et al. TCMSP:a database of systems pharmacology for drug discovery from herbal medicines[J]. J Cheminform,2014,6(1):13.
[7]魏志成,童东,杨娟,等.基于网络药理学的沙棘总黄酮治疗心肌缺血的作用机制研究[J].中国中药杂志,2017,42(7):1238.
[8] Gaulton A,Bellis L J,Bento A P,et al. ChEMBL:a large-scale bioactivity database for drug discovery[J]. Nucleic Acids Res,2012,40:1100.
[9] Li M,Chen J E,Wang J X,et al. Modifying the DPClus algorithm for identifying protein complexes based on new topological structures[J]. BMC Bioinformatics,2008,9(1):1.
[10] Chin C H,Chen S H,Wu H H,et al. cyto Hubba:identifying hub objects and sub-networks from complex interactome[J].BMC Syst Biol,2014,8(S4):S11.
[11] Tsai C J,Ma B,Nussinov R. Protein-protein interaction networks:how can a hub protein bind so many different partners[J]. Trends Biochem Sci,2009,34(12):594.
[12]陈晨,刘倩,高华.活血化瘀药药理作用研究进展[J].中国药事,2011,25(6):603.
[13]闫风.“五味学说”理论探讨[D].沈阳:辽宁中医药大学,2008.
[14]徐慧,董昌武.雌激素受体基因与心血管系统疾病相关性研究进展[J].医学综述,2013,19(9):1540.
[15] Hebertchatelain E. Src kinases are important regulators of mitochondrial functions[J]. Int J Biochem Cell B,2013,45(1):90.
[16] Dieliconwright C M,Spektor T M,Rice J C,et al. Oestradiol and SERM treatments influence oestrogen receptor coregulator gene expression in human skeletal muscle cells[J]. Acta Physiol,2010,197(3):187.
[17]傅文垚.三种神经退行性疾病相关基因互作网络和药物靶点的比较分析[D].合肥:合肥工业大学,2017.
[18]刘晓霞,翟曜耀,赵越.雌激素受体ERα的功能调控及相关疾病的研究进展[J].中国细胞生物学学报,2011,33(1):65.
[19]赵谊宁,陶陶,张力杰,等.雌激素受体ERα及ERβ与肿瘤关系的研究进展[J].东南大学学报:医学版,2016,35(3):418.
[20]王春战,景华.姜黄素抗炎抗氧化作用的研究进展[J].医学研究生学报,2012,25(6):658.
[21] Bagarolli R A,Saad M J A,Saad S T O. Toll-like receptor 4 and inducible nitric oxide synthase gene polymorphisms are associated with type 2 diabetes[J]. J Diabetes Complicat,2010,24(3):192.
[22]丰瑞兵,陈利锋,王华松,等.益气活血方对佐剂型关节炎大鼠滑膜组织TLR2、TLR9的影响[J].中医药导报,2017,23(17):25.
[23]吕春艳,吕邵娃,李国玉,等.中药复方性味与组分配伍药理效应的研究进展[J].中国中药杂志,2018,43(6):1099.
[24]庄晓峰.卡维地洛对大鼠急性心肌梗死后非梗死区胶原重塑及MMP-13/TIMP-2表达的影响[D].福州:福建医科大学,2006.
[25]肖斌,王耘,郭维嘉,等.中药药性组合及其与功效的关系研究[J].世界科学技术——中医药现代化,2010,12(6):902.
[26]李瑜.不同肾素型高血压患者的靶器官损害及其与ADRBK1基因变异的关联研究[D].乌鲁木齐:新疆医科大学,2015.
[27]姜萍,李晓,李寿松.从中药四气五味归经功效分析丁书文教授治疗高血压病用药特色[J].中华中医药杂志,2013,28(7):1951.
[28]刘晓妍,程宇琪,沈宗霖,等.抑郁症影像遗传学研究进展[J].国际精神病学杂志,2016,43(2):209.
[29]李卫国,付星,杜渐.针灸治疗抑郁症的理论探讨[J].中国中医基础医学杂志,2017,23(11):1596.
[30]陈万青,郑荣寿,张思维,等.2003~2007年中国癌症发病分析[J].中国肿瘤,2012,21(3):161.
[31]邓凯文.活血化瘀法在恶性肿瘤治疗中的应用研究[D].南京:南京中医药大学,2009.
[32]丁琦.当代活血化瘀法治疗肿瘤理论的演变与评价[D].济南:山东中医药大学,2017.
[33]马晓娟,殷惠军,陈可冀.血瘀证与炎症相关性的研究进展[J].中国中西医结合杂志,2007,27(7):669.
[34]马民.血瘀证形成的微观机制研究[D].济南:山东中医药大学,2003.